Company intelligence / Profile preview

Meribel Pharma

Ownership: Private
Development stage: Other

Overview

Meribel Pharma is a Danish biotechnology company focused on developing next-generation oral peptide therapies for metabolic diseases. Led by former Carmot Therapeutics CEO Stig Albinus, the company is leveraging advanced delivery technologies to transition injectable incretin mimetics, such as GLP-1 receptor agonists, into convenient oral formats. Meribel's mission is to improve patient access and compliance in the treatment of obesity and type 2 diabetes by overcoming the biological barriers to oral peptide absorption. The company represents a significant new player in the metabolic health space, building on the successful track record of its founding team in the incretin field.

Therapeutic areas: Endocrinology
Modalities: PeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Meribel Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meribel Pharma.

Explore the full profile